Sign In
Buy KNBWY
$16.48
+0.270 (+1.67%)
At Close: Jun 03, 2026
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responder
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
09:40am, Tuesday, 12'th May 2026
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML –
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
08:00am, Friday, 24'th Apr 2026
– Regulatory Filing in Japan Planned Following Clinical Trial Completion – – Regulatory Filing in Japan Planned Following Clinical Trial Completion –
Kyowa Kirin stops development of skin condition treatment
08:47am, Tuesday, 03'rd Mar 2026
Kyowa Kirin on Tuesday said it is discontinuing all ongoing trials of its experimental drug to treat skin conditions.
3 Reasons Growth Investors Will Love Kirin (KNBWY)
01:46pm, Monday, 09'th Feb 2026
Kirin (KNBWY) could produce exceptional returns because of its solid growth attributes.
Kirin (KNBWY) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Monday, 09'th Feb 2026
Kirin (KNBWY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Kirin (KNBWY) Stock Undervalued Right Now?
10:40am, Monday, 09'th Feb 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends
01:09pm, Friday, 30'th Jan 2026
Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ: AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.
TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, today announced the Board of Directors' decision to appoint Abdul Mullick,
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response an
SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
Should Value Investors Buy Kirin (KNBWY) Stock?
10:41am, Friday, 28'th Nov 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Princeton, NJ, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new clinical study data spotlighting the potential for
– NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients – – Acute unmet need in R/R NPM1-mutated AML defined by historically poor outcomes and low surviv
Is Kirin (KNBWY) Stock Outpacing Its Consumer Staples Peers This Year?
10:41am, Wednesday, 12'th Nov 2025
Here is how Kirin Holdings Co. (KNBWY) and Service Corp. (SCI) have performed compared to their sector so far this year.
